Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.

Todenhöfer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kühs U, Gerber V, Fetisch J, Schilling D, Hauch S, Stenzl A, Schwentner C.

Anticancer Res. 2012 Aug;32(8):3507-13.

PMID:
22843938
2.

Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.

Čapoun O, Mikulová V, Jančíková M, Honová H, Kološtová K, Sobotka R, Michael P, Zima T, Hanuš T, Soukup V.

Anticancer Res. 2016 Apr;36(4):2019-26.

PMID:
27069196
5.

Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.

Todenhöfer T, Hennenlotter J, Dorner N, Kühs U, Aufderklamm S, Rausch S, Bier S, Mischinger J, Schellbach D, Hauch S, Feniuk N, Bedke J, Gakis G, Stenzl A, Schwentner C.

J Cancer Res Clin Oncol. 2016 May;142(5):1013-20. doi: 10.1007/s00432-016-2129-0. Epub 2016 Feb 24.

PMID:
26910601
6.

Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.

Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S, Mavuduru RS, Prasad R.

Cancer Biomark. 2010-2011;8(2):81-7. doi: 10.3233/CBM-2011-0198.

PMID:
21896995
7.

Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.

Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ.

Urology. 2005 Mar;65(3):616-21.

PMID:
15780403
8.

Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, Sleijfer S.

Eur J Cancer. 2010 Jul;46(11):2027-35. doi: 10.1016/j.ejca.2010.03.030.

PMID:
20399640
9.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
10.

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Clin Genitourin Cancer. 2011 Sep;9(1):39-45. doi: 10.1016/j.clgc.2011.05.008. Epub 2011 Jul 1.

PMID:
21723797
11.

Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients.

Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D, Sabatier L, Chauveinc L.

Br J Cancer. 2004 Jan 26;90(2):443-8.

12.

Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction.

Ghossein RA, Osman I, Bhattacharya S, Ferrara J, Fazzari M, Cordon-Cardo C, Scher HI.

Diagn Mol Pathol. 1999 Jun;8(2):59-65.

PMID:
10475379
13.

Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.

O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW.

Clin Chem. 2004 May;50(5):826-35. Epub 2004 Feb 26.

14.

Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.

Thiounn N, Saporta F, Flam TA, Pages F, Zerbib M, Vieillefond A, Martin E, Debré B, Chevillard S.

Urology. 1997 Aug;50(2):245-50.

PMID:
9255296
15.

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B.

Clin Cancer Res. 2006 Sep 15;12(18):5578-86.

16.

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Apr 1;13(7):2023-9.

17.

Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.

Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P.

Int J Gynecol Cancer. 2011 Jul;21(5):822-30. doi: 10.1097/IGC.0b013e318216cb91.

PMID:
21613958
18.

Comparative chemosensitivity of circulating human prostate cancer cells and primary cancer cells.

Menen R, Zhao M, Zhang L, Hassanein MK, Bobek V, Kolostova K, Bouvet M, Hoffman RM.

Anticancer Res. 2012 Jul;32(7):2881-4.

PMID:
22753751
19.

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K.

Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22.

PMID:
20859679
20.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

Supplemental Content

Support Center